PDCD1 and esophageal squamous cell carcinoma: The study mainly observed the efficacy and safety/feasibility of using the combination of neoadjuvant PD-1 blockade with chemotherapy in patients with resectable ESCC, expecting to explore a more effective and less toxic neoadjuvant treatment regimen to improve the clinical outcomes of patients with ESCC.